In India, one in nine individuals has a lifetime risk of developing cancer. The number of cancer cases for the year 2022 (by the National Cancer Registry Program, India) was 14,61,427. Therefore, cancer prevention, control and treatment through early detection, risk reduction, advancements in drug discovery, and precision medicine are the need of the hour. Genetics and epigenetics play crucial roles in the development and progression of cancer. Genetic mutations, both inherited and acquired, can disrupt normal cellular processes, while epigenetic modifications can alter gene expression patterns. Hence, understanding these mechanisms is critical and paves the way for precision medicine, tailored treatment methods to target specific molecular abnormalities, and contribute to the advancement of cancer research, diagnosis, and treatment.
The objective of this conference is to provide the most recent concepts in the areas of genetics and epigenetics of cancer. With a focus on the most recent advancements in the subject, the conference features a diverse choice of presenters and speakers from renowned institutions and organizations in USA as well as in India. The two-day scientific convention fosters the development of enduring scientific communities and building research collaborations. In addition to the keynote address, and expert lectures the conference also features poster presentations. Additionally, it provides an opportunity for casual networking with eminent scientists in the field.
The focal point of the conference is to address the leading-edge technology and computing approaches that decipher the mechanistic insights attributed to the genome and epigenome studies. Technological advancements such as single-cell genomics and CRISPR-based tools and their application in unraveling the evolution and heterogeneity of cancer in terms of genetics, epigenetics, and genome topology will be addressed. The growing functions of the non-coding genome and epi-transcriptome in cancer and how they influence potential therapeutic approaches will be highlighted.
Difficulties in developing next-generation cancer genomics research and integrating vast amounts of cancer genomics data are other key aspects of this conference. Numerous cancer researchers, molecular biologists, and bioinformaticians who are interested in using the most recent genetic and epigenetic findings in their study of cancer should find this conference to be of utmost interest.